Tonabacase

N/A

Report date: 2024/12/23 15:33:34

Base Information

Drug NameTonabacase
Drug Alias NameN-Rephasin® SAL200SAL-200LSVT-1701
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionPeptidoglycan modulatorsCell wall inhibitors
TargetsPeptidoglycan
Therapy Area/IndicationsInfective EndocarditisEndocarditis, Non-InfectiveEndocarditis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIntron Biotechnology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntron Biotechnology IncBasilea Pharmaceutica LtdRoivant Sciences Inc +[4] 
Active IndicationsN/A
Inactive IndicationsInfective EndocarditisEndocarditis, Non-InfectiveEndocarditis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A